Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.

Autor: van Kempen LC; Department of Pathology, McGill University and OPTILAB-McGill University Health Center, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Pathology, Laboratory for Molecular Pathology, University Medical Center Groningen, Groningen, The Netherlands., Wang H; Department of Pathology, McGill University and OPTILAB-McGill University Health Center, Montreal, Quebec, Canada., Aguirre ML; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada., Spatz A; Department of Pathology, McGill University and OPTILAB-McGill University Health Center, Montreal, Quebec, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada., Kasymjanova G; Peter Brojde Lung Cancer Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: gkasymja@jgh.mcgill.ca., Vilacha JF; Department of Pharmacy, Structural Biology Unit Drug Design, University of Groningen, Groningen, The Netherlands., Groves MR; Department of Pharmacy, Structural Biology Unit Drug Design, University of Groningen, Groningen, The Netherlands., Agulnik J; Peter Brojde Lung Cancer Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada., Small D; Peter Brojde Lung Cancer Centre, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.
Jazyk: angličtina
Zdroj: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2018 Sep; Vol. 13 (9), pp. e161-e163. Date of Electronic Publication: 2018 Apr 25.
DOI: 10.1016/j.jtho.2018.04.020
Databáze: MEDLINE